Cerebral hypoperfusion: A new pathophysiologic concept in multiple sclerosis?

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 9, 2015, Pages 1406-1410

  D'Haeseleer, Miguel ^a,b   Hostenbach, Stéphanie ^a   Peeters, Ilse ^a   El Sankari, Souraya ^c   Nagels, Guy ^a,b,d   De Keyser, Jacques ^a,b,e   D'Hooghe, Marie B ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b National Multiple Sclerosis Center   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Faculté de Psychologie et des Sciences de L'Education   (Belgium)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bosentan; cerebral perfusion; endothelin 1; magnetic resonance imaging; multiple sclerosis

Indexed keywords

ENDOTHELIN 1;

ASTROCYTE; BRAIN BLOOD FLOW; BRAIN PERFUSION; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; BLOOD FLOW VELOCITY; BRAIN CIRCULATION; BRAIN ISCHEMIA; COGNITIVE DEFECT; DIFFUSE AXONAL INJURY; INFLAMMATION; METABOLISM; PATHOLOGY;

BLOOD FLOW VELOCITY; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; DIFFUSE AXONAL INJURY; ENDOTHELIN-1; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 84940718549     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.131     Document Type: Review

References (79)

1. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66: 1696-1702.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
3. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. JAMA Neurol 2004; 61: 1613-1615.
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. The N Eng J Med 2006; 354: 942-955.
5. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
6. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739-753.
7. Wilkins A, Scolding N. Protecting axons in multiple sclerosis. Mult Scler 2008; 14: 1013-1025.
8. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
9. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130: 1254-1262.
10. D'Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol 2011; 10: 657-666.
11. Wuerfel J, Paul F, Zipp F. Cerebral blood perfusion changes in multiple sclerosis. J Neurol Sci 2007; 259: 16-20.
12. Swank RL, Roth JG, Woody DC, Jr. Cerebral blood flow and red cell delivery in normal subjects and in multiple sclerosis. Neurol Res 1983; 5: 37-59.
13. Brooks DJ, Leenders KL, Head G, Marshall J, Legg NJ, Jones T. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosur Psychiatry 1984; 47: 1182-1191.
14. Lycke J, Wikkelso C, Bergh AC, Jacobsson L, Andersen O. Regional cerebral blood flow in multiple sclerosis measured by single photon emission tomography with technetium-99m hexamethylpropyleneamine oxime. Eur Neurol 1993; 33: 163-167.
15. Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med1998; 12: 89-94.
16. Law M, Saindane AM, Ge Y, Babb JS, Johnson G, Mannon LJ et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004; 231: 645-652.
17. Adhya S, Johnson G, Herbert J, Jaggi H, Babb JS, Grossman RI et al. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0T. NeuroImage. 2006; 33: 1029-1035.
18. Varga AW, Johnson G, Babb JS, Herbert J, Grossman RI, Inglese M. White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci 2009; 282: 28-33.
19. Papadaki EZ, Mastorodemos VC, Amanakis EZ, Tsekouras KC, Papadakis AE, Tsavalas ND et al. White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome. Magn Reson Med 2012; 68: 1932-1942.
20. Rashid W, Parkes LM, Ingle GT, Chard DT, Toosy AT, Altmann DR et al. Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 1288-1293.
21. Ge Y, Law M, Johnson G, Herbert J, Babb JS, Mannon LJ et al. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol 2005; 26: 1539-1547.
22. Haselhorst R, Kappos L, Bilecen D, Scheffler K, Mori D, Radu EW et al. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 2000; 11: 495-505.
23. Wuerfel J, Bellmann-Strobl J, Brunecker P, Aktas O, McFarland H, Villringer A et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004; 127: 111-119.
24. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 392-399.
25. Singh AV, Zamboni P. Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009; 29: 1867-1878.
26. Zivadinov R, Marr K, Cutter G, Ramanathan M, Benedict RH, Kennedy C et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011; 77: 138-144.
27. Ge Y, Zohrabian VM, Osa EO, Xu J, Jaggi H, Herbert J et al. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging 2009; 29: 1190-1194.
28. Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den Berg R et al. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry 2011; 82: 429-435.
29. El Sankari S, Baledent O, van Pesch V, Sindic C, de Broqueville Q, Duprez T. Concomitant analysis of arterial, venous, and CSF flows using phase-contrast MRI: a quantitative comparison between MS patients and healthy controls. J Cereb Blood Flow Metab 2013; 33: 1314-1321.
30. Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron 2011; 71: 782-797.
31. Saindane AM, Law M, Ge Y, Johnson G, Babb JS, Grossman RI. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol 2007; 28: 767-772.
32. Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC et al. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 544-551.
33. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996; 7: 1397-1400.
34. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
35. Cambron M, D'Haeseleer M, Laureys G, Clinckers R, Debruyne J, De Keyser J. White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab 2012; 32: 413-424.
36. Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W. Reduced NAAlevels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3Tesla. PLoS One 2010; 5: e11625.
37. Steen C, D'Haeseleer M, Hoogduin JM, Fierens Y, Cambron M, Mostert JP et al. Cerebral white matter blood flow and energy metabolism in multiple sclerosis. Mult Scler 2013; 19: 1282-1289.
38. Corti A, Lenzi D, Frasca V, Gilio F, Giacomelli E, Gabriele M et al. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis. J Neurol 2009; 256: 933-938.
39. Vucic S, Burke T, Lenton K, Ramanathan S, Gomes L, Yannikas C et al. Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler 2012; 18: 425-432.
40. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
41. De Keyser J, Steen C, Mostert JP, Koch MW. Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab 2008; 28: 1645-1651.
42. Marshall O, Lu H, Brisset JC, Xu F, Liu P, Herbert J et al. Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol 2014; 71: 1275-1281.
43. Speciale L, Sarasella M, Ruzzante S, Caputo D, Mancuso R, Calvo MG et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 2000; 6(Suppl 2): S62-S66.
44. Haufschild T, Shaw SG, Kesselring J, Flammer J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 2001; 21: 37-38.
45. Pache M, Kaiser HJ, Akhalbedashvili N, Lienert C, Dubler B, Kappos L et al. Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. Eur Neurol 2003; 49: 164-168.
46. D'Haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C et al. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci USA 2013; 110: 5654-5658.
47. Piechota A, Polanczyk A, Goraca A. Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress. Pharmacol Rep 2010; 62: 28-34.
48. Nie XJ, Olsson Y. Endothelin peptides in brain diseases. Rev Neurosci 1996; 7: 177-186.
49. Ostrow LW, Langan TJ, Sachs F. Stretch-induced endothelin-1 production by astrocytes. J Cardiovas Pharmacol 2000; 36(Suppl 1): S274-S277.
50. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
51. Aliev G, Obrenovich ME, Smith MA, Perry G. Hypoperfusion, mitochondria failure, oxidative stress, and Alzheimer disease. J Biomed Biotechnol 2003; 2003: 162-163.
52. Stys P. White matter injury mechanisms. Curr Mol Med 2004; 4: 109-126.
53. Wakita H, Tomimoto H, Akiguchi I, Matsuo A, Lin JX, Ihara M et al. Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res 2002; 924: 63-70.
54. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004; 5: 437-448.
55. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13: 554-573.
56. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37: 1391-1398.
57. Markus HS, Lythgoe DJ, Ostegaard L, O'Sullivan M, Williams SC. Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI. J Neurol Neurosurg Psychiatry 2000; 69: 48-53.
58. Hong LZ, Zhao XY, Zhang HL. p53-mediated neuronal cell death in ischemic brain injury. Neurosci Bull 2010; 26: 232-240.
59. Wosik K, Antel J, Kuhlmann T, Bruck W, Massie B, Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem 2003; 85: 635-644.
60. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
61. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25-33.
62. Juurlink BH. The evidence for hypoperfusion as a factor in multiple sclerosis lesion development. Mult Scler Int 2013; 2013: 598093.
63. Rosso C, Remy P, Creange A, Brugieres P, Cesaro P, Hosseini H. Diffusion-weighted MR imaging characteristics of an acute strokelike form of multiple sclerosis. AJNR Am J Neuroradiol 2006; 27: 1006-1008.
64. Holland CM, Charil A, Csapo I, Liptak Z, Ichise M, Khoury SJ et al. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1, 249 patients with multiple sclerosis. J Neuroimaging 2012; 22: 129-136.
65. Ota M, Sato N, Nakata Y, Ito K, Kamiya K, Maikusa N et al. Abnormalities of cerebral blood flow in multiple sclerosis: a pseudocontinuous arterial spin labeling MRI study. Magn Reson Imaging 2013; 31: 990-995.
66. Narayana PA, Zhou Y, Hasan KM, Datta S, Sun X, Wolinsky JS. Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis. Mult Scler 2014; 20: 365-373.
67. Inglese M, Adhya S, Johnson G, Babb JS, Miles L, Jaggi H et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008; 28: 164-171.
68. Francis PL, Jakubovic R, O'Connor P, Zhang L, Eilaghi A, Lee L et al. Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosis. AJNR Am J Neuroradiol 2013; 34: 62-67.
69. Aviv RI, Francis PL, Tenenbein R, O'Connor P, Zhang L, Eilaghi A et al. Decreased frontal lobe gray matter perfusion in cognitively impaired patients with secondary-progressive multiple sclerosis detected by the bookend technique. AJNR Am J Neuroradiol 2012; 33: 1779-1785.
70. D'Haeseleer M, Steen C, Hoogduin JM, van Osch MJ, Fierens Y, Cambron M et al. Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis. Acta Neurol Scand 2013; 128: e26-e29.
71. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Subcortical vascular cognitive impairment: similarities and differences with multiple sclerosis. J Neurol Sci 2006; 245: 3-7.
72. Inglese M, Park SJ, Johnson G, Babb JS, Miles L, Jaggi H et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. JAMA Neurol 2007; 64: 196-202.
73. Vucic S, Burke D, Kieman M. Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol 2010; 121: 809-817.
74. Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie JX et al. Structural and vasoactive factors influencing intracerebral arterioles in cases of vascular dementia and other cerebrovascular disease: a review. Immunohistochemical studies on expression of collagens, basal lamina components and endothelin-1. Dementia 1994; 5: 153-162.
75. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-612.
76. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
77. Konsman JP, Drukarch B, Van Dam AM. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci 2007; 112: 1-25.
78. De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999; 53: 1628-1633.
79. Pelletier S, Battistini B, Sirois P. Adenosine-induced inhibition of basal endothelin-1 production from guinea-pig tracheal epithelial cells: a mechanism involving the release of cAMP. Pulm Pharmacol Ther 1998; 11: 237-242.